# Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

> **NCT03283137** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of Chicago** · enrollment: 20 (actual)

## Conditions studied

- CLL
- B-cell Non Hodgkin Lymphoma

## Interventions

- **DRUG:** TGR-1202
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03283137
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-01-23
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03283137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03283137, "Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03283137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*